Literature DB >> 8498419

Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis.

T M Price1, R E Dupuis, B R Carr, F Z Stanczyk, R A Lobo, W Droegemueller.   

Abstract

OBJECTIVE: Our purpose was to compare the pharmacokinetic parameters of oral administration of a 35 micrograms ethinyl estradiol, 1 mg norethindrone pill in peritoneal dialysis patients and normal women. STUDY
DESIGN: A single-dose study was performed with five patients and four controls, followed by a multiple-dose study with five subjects in each group. Pharmacokinetic parameters were calculated by noncompartmental analysis and statistical analysis performed with Mann-Whitney U testing.
RESULTS: There is no difference in the pharmacokinetic parameters for norethindrone in peritoneal dialysis patients compared with normal women. During multiple dosing an increased area under the concentration curve and decreased apparent oral clearance was observed for ethinyl estradiol in peritoneal dialysis patients compared with normal women.
CONCLUSION: Peritoneal dialysis patients have decreased apparent oral clearance of ethinyl estradiol, leading to slightly higher serum concentrations compared with women with normal renal function. The clearance of norethindrone is the same in peritoneal dialysis patients and normal women.

Entities:  

Keywords:  Americas; Biology; California; Case Control Studies; Clinical Research; Contraception; Contraceptive Agents, Estrogen--pharmacodynamics; Contraceptive Agents, Female--pharmacodynamics; Contraceptive Agents, Progestin--pharmacodynamics; Contraceptive Agents--pharmacodynamics; Contraceptive Methods--administraction and dosage; Contraceptive Methods--pharmacodynamics; Contraceptive Methods--therapeutic use; Developed Countries; Ethinyl Estradiol--pharmacodynamics; Family Planning; Norethindrone--pharmacodynamics; North America; North Carolina; Northern America; Oral Contraceptives, Low-dose--administraction and dosage; Oral Contraceptives, Low-dose--pharmacodynamics; Oral Contraceptives, Low-dose--therapeutic use; Oral Contraceptives--administraction and dosage; Oral Contraceptives--pharmacodynamics; Oral Contraceptives--therapeutic use; Physiology; Renal Effects; Research Methodology; Studies; Texas; Treatment; United States; Urogenital Effects; Urogenital System

Mesh:

Substances:

Year:  1993        PMID: 8498419     DOI: 10.1016/s0002-9378(11)90772-8

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  5 in total

1.  Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women.

Authors:  Carolyn L Westhoff; Anupama H Torgal; Elizabeth R Mayeda; Malcolm C Pike; Frank Z Stanczyk
Journal:  Contraception       Date:  2010-02-20       Impact factor: 3.375

2.  Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding.

Authors:  Anne R Davis; Carolyn L Westhoff; Frank Z Stanczyk
Journal:  Epilepsia       Date:  2011-01-04       Impact factor: 5.864

3.  Combined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi.

Authors:  Gretchen S Stuart; Agnes Moses; Amanda Corbett; Grace Phiri; Wiza Kumwenda; Nkhafwire Mkandawire; Joseph Chintedze; Gabriel Malunga; Mina Hosseinipour; Myron S Cohen; Frank Z Stanczyk; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2011-10-01       Impact factor: 3.731

4.  Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity.

Authors:  Alison B Edelman; Nichole E Carlson; Ganesh Cherala; Myrna Y Munar; Richard L Stouffer; Judy L Cameron; Frank Z Stanczyk; Jeffrey T Jensen
Journal:  Contraception       Date:  2009-06-04       Impact factor: 3.375

5.  Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women.

Authors:  Jessica Atrio; Frank Z Stanczyk; Michael Neely; Ganesh Cherala; Andrea Kovacs; Daniel R Mishell
Journal:  J Acquir Immune Defic Syndr       Date:  2014-01-01       Impact factor: 3.731

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.